HBA1C AS AN INDIRECT MARKER OF HYPERTRIGLYCERIDEMIA IN TYPE 2 DIABETES MELLITUS
AbstractBackground: Diabetes is usually accompanied by dyslipidaemia, and among these triglyceride levels are related to the insulin resistance in type 2 diabetes. HbA1c which is an indicator of diabetes control can depict the severity of hypertriglyceridemia. The objective of this study was to determine the correlation between HbA1c and Triglyceride levels in type 2 Diabetes mellitus. Methods: A sample of 150 diabetic patients fulfilling the inclusion and exclusion criteria were selected for this cross-sectional study .Patient included were type 2 Diabetes Mellitus with HbA1c ≥7. Patients with history of cardiovascular disease, taking lipid lowering medications, smoker and history of cerebral stroke were excluded. HbA1c and triglyceride levels were noted .Study patients were further stratified on the basis of severity of HbA1c and Triglyceride values. The correlation between HbA1c and Triglyceride levels were established with Pearson Correlation. Results: Among total number of 150 patients 44% (n=70) were male and 50.3% (n=80) were female. The correlation of HbA1c with Triglyceride as estimated by Pearson Correlation was positive (p=0.033, r=0.033) and statistically significant. Conclusions: In type 2 diabetes mellitus there is a predictable relationship between Triglycerides and HbA1c
Berry C, Tardif JC, Bourassa MG . Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol 2007;49(6):631–42.
Sultan A, Thuan JF, Avignon A. Primary prevention of cardiovascular events and type 2 diabetes: should we prioritize our interventions? Diabetes Metab 2006;32(6):559–67.
A Bener A, Zirie M, Mohammed H, Daghash, Abdulla OAA, Al-Hamaq, et al. Lipids, lipoprotein (a) profile and HbA1c among Arabian Type 2 diabetic patients. Biomed Res 2007;18(2): 97–102.
Betteridge DJ. Diabetic dyslipidemia. Diabetes Obes Metab 2006;2:31–6.
Ginsberq HN. Identification and treatment of hypertriglyceridemia as a risk factor for coronary heart disease. Curr Cardiol Rep 1999;1(3): 233–7.
Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56(14):1113–32.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339(4):229–34.
Windler E. What is the consequence of an abnormal lipid profile in patients with type 2
diabetes or the metabolic syndrome? Atheroscler Suppl 2005;6(3):11–4.
Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 2000;106(4):453–8.
Goldschmid MG, Barrett-Connor E, Edelstein SL, Wingard DL, Cohn BA, Herman WH. Dyslipidaemia and ischemic heart disease mortality among men and women with diabetes. Circulation 1994;89(3):991–7.
Manson JE, Colditz GA, Stamper MJ, Willet WC, Krolewski AS, Rosner B, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151:1141–7.
Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986;112(2):432–7.
Ahmad J, Hameed B, Das G, Siddiqui MA, Ahmad I. Postprandial hypertriglyceridemia and carotid intima-media thickness in north Indian type 2 diabetic subjects. Diabetes Res Clin Pract 2005;69(2):142–50.
Rashid A, Haider I. Correlation of serum lipid profile with glycemic control in type 2 diabetics. J Postgraduate Med Inst 2009;23(3):231–5.
Perez A, Wagner AM, Carreras G, Giménez G, Sánchez-Quesada JL, Rigla M, et al. Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus:effect of glycemic control. Arch Intern Med 2006;160(18):2756–62.
Alagözlü H, Gültekin F, Candan F. Lipid and lipoprotein patterns in type 2 non-obese
diabetic patients Do LP(a) levels decrease with improved glycemic control in these patients? Nutr Metab Cardiovasc Dis 2005;10(4):204–8.
Amer W, Zafar S, Majrooh A. Comparison of dyslipidemias in controlled and uncontrolled type 2 diabetics. Ann King Edward Med Coll 2004;10:158–60.
Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2006;29(4):877–82.
Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Pro-spective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001;322(7277):15–8.